Skip to content

A Prospective Study of Functional Magnetic Resonance Imaging in Evaluating and Predicting Chemo-radiotherapeutic Response of Locally Advanced Head and Neck Squamous Cell Carcinoma

A Prospective Study of Functional Magnetic Resonance Imaging in Evaluating and Predicting Chemo-radiotherapeutic Response of Locally Advanced Head and Neck Squamous Cell Carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100042863
Enrollment
Unknown
Registered
2021-01-30
Start date
2021-02-01
Completion date
Unknown
Last updated
2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

Gold Standard:RECIST Version 1.1
magnetic&#32
resonance&#32
imaging&#32
of&#32
and&#32

Sponsors

First Medical Center of Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. In patients with HNSCC, the primary sites included pharynx (including nasopharynx, oropharynx, hypopharynx), larynx, nasal cavity and paranasal sinuses; 2. Patients with definite pathological diagnosis and clinical staging of locally advanced tumors (according to AJCC 8th Edition head and neck tumor staging criteria: T1-4 N2-3 M0 but not T1-2 N1 M0, T3-4 n0-1 M0); 3. For subjects with KPS score >= 70, ECoG score: 0-1; 4. Subjects aged 18-70 years old; 5. Subjects who can tolerate plain and enhanced MRI examination; 6. Imaging examination (plain MRI + enhanced MRI); The range of primary lesion invasion and lymph node metastasis were confirmed by color Doppler ultrasound (CDFI); 7. Subjects with normal liver and kidney function, without severe hematologic toxicity and severe medical complications, were allowed to participate in induction chemotherapy, concurrent chemotherapy, consolidation chemotherapy, targeted therapy and other treatment methods; 8. Subjects without surgical intervention; 9. Volunteers who signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients over 70 years old; 2. For patients whose KPS score was less than 70, ECoG score was more than 1; 3. Patients with liver and kidney dysfunction, severe hematologic toxicity and medical complications can not be treated with induction chemotherapy or synchronous chemotherapy; 4. Patients with previous head and neck radiotherapy history; 5. Patients with denture, prosthesis and other metal implants; 6. Claustrophobic patients.

Design outcomes

Primary

MeasureTime frame
ADC;MD/MK;IVIM (Dslow/Dfast/PF);DCE-MRI (Ktrans/Ve/Kep);

Countries

China

Contacts

Public ContactLin Ma

Department of Radiotherapy, First Medical Center, General Hospital of Chinese People's Liberation Army

malinpharm@sina.com+86 13911197589

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 20, 2026